Role of Positron Emission Tomography as a Biologic Marker in the Diagnosis of Primary Progressive Aphasia: Two Case Reports
Primary progressive aphasia (PPA) is a heterogenous neurodegenerative disorder characterized by declining language and speech ability. Various underlying neuropathologies can induce PPA, and the disorder is divided into three subtypes—progressive non-fluent aphasia, semantic variant aphasia, and logopenic aphasia—according to clinical features. Accurate disease classification and prediction of underlying diseases are necessary for appropriate treatment, but proper use of imaging tests is important because clinical information alone often makes it difficult to make accurate decisions. Because there is a characteristic metabolic pattern according to the subtypes, F-18 fluorodeoxyglucose positron emission tomography (PET) can indicate subtype classification. In addition, PET studies for imaging amyloid or dopamine transporters play an important role in demonstrating underlying disease. The present case showed that PET imaging studies are useful in diagnosis and could be used as a biomarker in PPA.
KeywordsPrimary progressive aphasia Positron emission tomography Fluorodeoxyglucose Amyloid Dopamine transporter Biomarker
Compliance with Ethical Standards
Conflict of Interest
Young Jin Jeong, Kyung Won Park, and Do-Young Kang declare that they have no conflict of interest.
This article is a case report for which approval by an institutional review board is waived.
Informed consent was obtained from all subjects of this case report.